Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Hepion Pharmaceuticals, Inc.
- Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
- 15
- 1.00
The cost to borrow HEPA shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 7.7%
- 17.7K
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 15 sh |
| Oct 15, 2026 | 3.9K sh |
| Sep 30, 2026 | 14.9K sh |
| Sep 15, 2026 | 4.8K sh |
| Aug 31, 2026 | 3.5K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Aug 14, 2026 | 17.7K sh |
| Jul 9, 2026 | 1 sh |
| Apr 20, 2026 | 1 sh |
| Apr 17, 2026 | 1 sh |
| Apr 16, 2026 | 1 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 7.7% |
| Nov 16, 2026 | 81.3% |
| Nov 13, 2026 | 0.0% |
| Nov 12, 2026 | 0.3% |
| Nov 6, 2026 | 12.6% |
130 calendar days requested; 74 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for HEPA: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 15 HEPA shares were sold short (1.00 days to cover).